WO2003029465A1 - Gene hepnadc - Google Patents
Gene hepnadc Download PDFInfo
- Publication number
- WO2003029465A1 WO2003029465A1 PCT/JP2002/010038 JP0210038W WO03029465A1 WO 2003029465 A1 WO2003029465 A1 WO 2003029465A1 JP 0210038 W JP0210038 W JP 0210038W WO 03029465 A1 WO03029465 A1 WO 03029465A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hepnadc
- gene
- polypeptide
- antibody against
- expression product
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title abstract 3
- 210000004027 cell Anatomy 0.000 abstract 3
- 229920001184 polypeptide Polymers 0.000 abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 3
- 108020003264 Cotransporters Proteins 0.000 abstract 1
- 108020004414 DNA Proteins 0.000 abstract 1
- 102000053602 DNA Human genes 0.000 abstract 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 230000004071 biological effect Effects 0.000 abstract 1
- 235000019577 caloric intake Nutrition 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000013604 expression vector Substances 0.000 abstract 1
- 210000003494 hepatocyte Anatomy 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 108091033319 polynucleotide Proteins 0.000 abstract 1
- 102000040430 polynucleotide Human genes 0.000 abstract 1
- 239000002157 polynucleotide Substances 0.000 abstract 1
- 229910052708 sodium Inorganic materials 0.000 abstract 1
- 239000011734 sodium Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Toxicology (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
L'invention concerne un gène cotransporteur de di- ou tricarboxylate de sodium (gène HepNaDC) exprimé dans des cellules HepG2 d'origine cancéreuse de l'hépatocyte humain, par exemple, une molécule d'ADN contenant un polynucléotide codant un polypeptide comprenant la séquence d'acide amino représentée par SEQ ID NO :1 ; son vecteur d'expression ; des cellules hôtes le portant ; un produit d'expression produit par les cellules ; un anticorps agissant à l'encontre du produit d'expression ; des médicaments contenant ledit anticorps comme principe actif, etc. L'utilisation de ce gène permet de produire un polypeptide HepNaDC, un anticorps agissant à son encontre, comme un antigène, etc. En outre, l'activité biologique du polypeptide HepNaDC peut être inhibée de sorte qu'un constituant candidat utile dans la prévention/le traitement de diabètes ou de l'obésité ou dans le contrôle de prise de calories puisse être sélectionné.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2001-299433 | 2001-09-28 | ||
| JP2001299433 | 2001-09-28 | ||
| JP2002-249016 | 2002-08-28 | ||
| JP2002249016A JP2003169688A (ja) | 2001-09-28 | 2002-08-28 | ＨｅｐＮａＤＣ遺伝子 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2003029465A1 true WO2003029465A1 (fr) | 2003-04-10 |
Family
ID=26623219
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/JP2002/010038 WO2003029465A1 (fr) | 2001-09-28 | 2002-09-27 | Gene hepnadc |
Country Status (2)
| Country | Link |
|---|---|
| JP (1) | JP2003169688A (fr) |
| WO (1) | WO2003029465A1 (fr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5463531B2 (ja) * | 2009-07-22 | 2014-04-09 | 国立大学法人 東京大学 | Ｐｈｄ２発現抑制物質搭載ポリイオンコンプレックス |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020019028A1 (en) * | 2000-06-13 | 2002-02-14 | Kabir Chaturvedi | Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof |
-
2002
- 2002-08-28 JP JP2002249016A patent/JP2003169688A/ja active Pending
- 2002-09-27 WO PCT/JP2002/010038 patent/WO2003029465A1/fr active Application Filing
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020019028A1 (en) * | 2000-06-13 | 2002-02-14 | Kabir Chaturvedi | Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof |
Non-Patent Citations (2)
| Title |
|---|
| PAJOR A.M. ET AL.: "Molecular cloning and functional expression of a sodium-dicarboxylate cotransporter from human kidney", AM. J. PHYSIOL., vol. 270, no. 4, PT. 2, 1996, pages F642 - F648, XP002961004 * |
| PAJOR A.M. ET AL.: "Sequence and functional characterization of a renal sodium/dicarboxylate cotransporter", J. BIOL. CHEM., vol. 270, no. 11, 1995, pages 5779 - 5785, XP002961005 * |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2003169688A (ja) | 2003-06-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Brines et al. | Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin | |
| Khaitovich et al. | Reconstitution of functionally active Thermus aquaticus large ribosomal subunits with in vitro-transcribed rRNA | |
| Prorok et al. | Calcium binding properties of synthetic γ-carboxyglutamic acid-containing marine cone snail “sleeper” peptides, conantokin-G and conantokin-T | |
| AU735355C (en) | Novel protein and method for producing the protein | |
| RU2418002C2 (ru) | Способ получения фактора, связанного с контролем над потреблением пищи и/или массой тела, полипептид, обладающий активностью подавления потребления пищи и/или прибавления в весе, молекула нуклеиновой кислоты, кодирующая полипептид, способы и применение полипептида | |
| NO20050998L (no) | DNA som koder for et biologisk aktivt fragment av baktericid/premeabilitetsokende protein fremgangsmate for fremstilling av dette, samt farmasoytisk preparat inneholdende dette | |
| WO2003020932A1 (fr) | Nouvelles proteines de secretion et adn associe | |
| WO2003093316A3 (fr) | Molecule a reconnaissance de la surface des cellules contenant un domaine d'immunoglobuline | |
| BRPI0412607A (pt) | método para aprimorar a eficácia de proteìnas modificantes de reação biológica e muteìnas resultantes | |
| Gill et al. | Nickel-dependent oxidative cross-linking of a protein | |
| Håkansson et al. | Structure of peptidase T from Salmonella typhimurium | |
| DE60235985D1 (de) | Ntb-a, ein oberflächenmolekül impliziert in der aktivität natürlicher killerzellen (nk) | |
| Cathcart et al. | Inhibitor profiling of the Pseudomonas aeruginosa virulence factor LasB using N-alpha mercaptoamide template-based inhibitors | |
| WO2002004487A3 (fr) | Procede d'extraction et d'utilisation de nouvelles defensines humaines en tant que proteines biologiquement actives pour traiter des infections et autres pathologies | |
| WO2003029465A1 (fr) | Gene hepnadc | |
| Takagi et al. | Functional analysis of the propeptides of subtilisin E and aqualysin I as intramolecular chaperones | |
| Váradi et al. | Confirmation of the disulfide connectivity and strategies for chemical synthesis of the four-disulfide-bond-stabilized Aspergillus giganteus antifungal protein, AFP | |
| DK0659883T3 (da) | Protein p140 og DNA, der koder for dette | |
| Boyle et al. | Use of the design‐of‐experiments approach for the development of a refolding technology for progenipoietin‐1, a recombinant human cytokine fusion protein from Escherichia coli inclusion bodies | |
| Mooney et al. | N‐terminal processing of affinity‐tagged recombinant proteins purified by IMAC procedures | |
| Doneanu et al. | Mass Spectrometry of UV-Cross-Linked Protein− Nucleic Acid Complexes: Identification of Amino Acid Residues in the Single-Stranded DNA-Binding Domain of Human Replication Protein A | |
| D'Souza et al. | Extracellular glucose concentration alters functional activity of the intestinal oligopeptide transporter (PepT-1) in Caco-2 cells | |
| DE60135650D1 (de) | Amidotransferase und dessen expressionsprodukt | |
| WO2006018450A3 (fr) | Molecules pharmaceutiquement actives modulant le recepteur de l'insuline | |
| RU93031156A (ru) | Способ получения плазмид, кодирующих химерный белок с последовательностью соматостатина, штамм бактерий escherichia coli - продуцент этого белка, белок, полученный в этом штамме, содержащий фрагмент ацетилтрансферазы, спейсер и иммуногенный соматостатин |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA CN KR MX SG |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FR GB GR IE IT LU MC NL PT SE SK TR |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| 122 | Ep: pct application non-entry in european phase |